{
    "clinical_study": {
        "@rank": "55285", 
        "arm_group": {
            "arm_group_label": "Vinorelbine cisplatin radiotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Induction period + radio chemotherapy"
        }, 
        "brief_summary": {
            "textblock": "Patients (pts) with stage IIIA/IIIB NSCLC received NVBiv 25 mg/m\u00b2 + CDDP 80 mg/m\u00b2 on D1 and\n      NVBo 60 mg/m\u00b2 on D8 every 3 weeks (q3w) for 2 cycles as induction. Pts with response or non\n      change received NVBo 20 mg fixed dose on D1 D3 D5 + CDDP 80 mg/m\u00b2 on D1 q3w for 2 more\n      cycles during RT(66 Gy/6.5 w)."
        }, 
        "brief_title": "Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy", 
        "completion_date": {
            "#text": "October 2008", 
            "@type": "Actual"
        }, 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": "Lung Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Vinorelbine (NVB) + CDDP is considered a standard trt in induction or concomitantly with RT\n      (Vokes, Fournel, Krzakowski). NVBo simplifies the administration of trt and provides the\n      same efficacy as intravenous NVB (NVBiv). In order to assess this and to improve the\n      tolerance, a trial was started with NVBiv and NVBo + CDDP as induction followed by a\n      fractionated administration of NVBo + CDDP during RT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically or cytologically confirmed stage IIIA (only N2),\n\n          -  dry IIIB previously untreated inoperable NSCLC,\n\n          -  18 to 75 years old,\n\n          -  Karnofsky Performance Status (KPS) \u2265 80%,\n\n          -  weight loss \u2264 10% within the previous 3 months,\n\n          -  normal organ functions were eligible.\n\n          -  at least one measurable lesion according to Response Evaluation Criteria in Solid\n             Tumors (RECIST version 1.0) [10].\n\n        Exclusion Criteria:\n\n          -  stages I, II, IIIA (excepted N2), IIIB with pleural effucion and stage IV,\n\n          -  pregnant or breastfeeding women. Women of Childbearing Age: Women of childbearing\n             potential should take reliable contraceptive measures\n\n          -  Symptomatic Neuropathy > grade 1,\n\n          -  associated Pathology and/or not controled diseases(cardiac insuficiency, myocardial\n             infarction within 3 months before the inclusion ; hypertension, arythmia or\n             uncontroled hypercalc\u00e9mia; infection requiering iv antibiotic administration within 2\n             weeks before inculion),\n\n          -  other associated cancer with the exception of cervical carcinoma in situ or skin\n             cancer baso-cellular correctely treated,\n\n          -  Previous treatment with an other antineoplasic,\n\n          -  Known hypersensibility to drugs with a similar chemical structure ti this studied.\n\n          -  important malabsorbtion syndrom or disease of gastro-intestinal track,\n\n          -  Participation to another clinical trial within 30 days before inclusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01839032", 
            "org_study_id": "041316"
        }, 
        "intervention": {
            "arm_group_label": "Vinorelbine cisplatin radiotherapy", 
            "description": "During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m\u00b2, was administered on day 1, then cisplatin 80 mg/m\u00b2 was administered over 1-hour infusion. Vinorelbine 60 mg/m\u00b2 was also administered on day 8.\nPatients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m\u00b2 66 Gy).", 
            "intervention_name": "Vinorelbine cisplatin radiotherapy", 
            "intervention_type": "Drug", 
            "other_name": "Navelbine"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vinorelbine", 
                "Cisplatin", 
                "Vinblastine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Caen", 
                    "country": "France", 
                    "zip": "14033"
                }, 
                "name": "CHU CAEN"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Cisplatin With Intravenous and Oral Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemotherapy With Oral Vinorelbine and Cisplatine for Locally Advances Non-small Cell Lung Cancer", 
        "other_outcome": [
            {
                "measure": "- progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "- overall survival (OS),", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "- safety", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 years"
            }
        ], 
        "overall_official": {
            "affiliation": "Baclesse, Caen, France", 
            "last_name": "G\u00e9rard Zalcmann, professor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Disease controle", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01839032"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Secondary endpoints were duration of response (DR), progression-free survival (PFS), and overall survival (OS), calculated by the Kaplan-Meier method. The safety analysis reported the worst grade of the adverse events (NCI CTC v. 2.0) for the safety population.", 
            "measure": "- duration of response (DR)", 
            "safety_issue": "No", 
            "time_frame": "up to 3 years"
        }, 
        "source": "Pierre Fabre Medicament", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pierre Fabre Medicament", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2005", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}